SELECT PUBLICATIONS

Albain K et al. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). San Antonio Breast Cancer Symposium 2004;Abstract 37.

Arriagada R et al. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol 2005;44(5):458- 66. Abstract

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Cobleigh MA et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005;11(24 Pt 1):8623-31. Abstract

Doyle JJ et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005;23(34):8597-605. Abstract

Duric VM et al. Patients’ preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Ann Oncol 2005;16(11):1786-94. Abstract

Eiermann W et al. Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study. San Antonio Breast Cancer Symposium 2005;Abstract 1069.

Fisher B et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989;7(5):572-82. Abstract

Goldhirsch A et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16(10):1569-83. Abstract

Goldstein L et al. E2197: Phase III AT (doxorubicin/docetaxel) vs AC (doxorubicin/cyclo-
phosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proc ASCO 2005;Abstract 512.

Harlan LC et al. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. J Clin Oncol 2006;24(6):872-7. Abstract

Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41.

Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 40.

Kaklamani VG, Gradishar WJ. Adjuvant therapy of breast cancer. Cancer Invest 2005;23(6):548-60. Abstract

Kaufmann M, Rody A. Long-term risk of breast cancer recurrence: The need for extended adjuvant therapy. J Cancer Res Clin Oncol 2005;131(8):487-94. Abstract

Levine MN et al; National Cancer Institute of Canada Clinical Trials Group. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23(22):5166-70. Abstract

Mamounas E et al. Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: Results from NSABP B-14 and NSABP B-20. San Antonio Breast Cancer Symposium 2005;Abstract 29.

Mamounas EP et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 2005;23(16):3686-96. Abstract

Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract

Paik S. Methods for gene expression profiling in clinical trials of adjuvant breast cancer therapy. Clin Cancer Res 2006a;12(3 Pt 2):1019-23. Abstract

Paik S. Molecular profiling of breast cancer. Curr Opin Obstet Gynecol 2006b;18(1):59-63. Abstract

Paik S et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351(27):2817-26. Abstract

Sparano JA et al. Phase III study of doxorubicin-cyclophosphamide followed by pacli­taxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: Results of North American Breast Cancer Intergroup Trial E1199. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 48.